A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 253 participants.

Also called NCT01056731

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 253 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01056731
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Venezuela (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01056731. Allocation not applicable; no masking; primary purpose treatment. Start 2010-02 (registry gives no type); primary completion 2011-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients.
Acronym
ANDROMEDA
Intervention (Drug)
Aliskiren and HCTZ
Lead sponsor
Novartis (class: industry)

Record details

Record id
cardio:ct-nct01056731
Content hash
3b85fdacfe9819dc48d98c68917df775fb1cf3ee8f692ea300e16d4ed2db3758